Molecular disparity of HLA‐DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation
Abstract
BackgroundAn increased incidence of subsequent solid cancers (SSCs) has been reported in long-term survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT), and SSC is associated with inferior mortality and morbidity. Previous studies showed that the incidence of SSC is significantly higher in those who underwent allo-HSCT from HLA-mismatched donors, suggesting that persistent alloimmunity may predispose patients to SSCs. It was recently reported that, in a cohort of patients who received allo-HSCT from an unrelated donor matched at HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1 loci, HLA-DPB1 alloimmunity determined by high mismatched eplets (MEs) and Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) score (PS), was associated with relapse protection and increased risk of acute graft-versus-host disease (GVHD). MethodsIn the present study, the impact of HLA-DPB1 alloimmunity assessed by molecular mismatch algorithms on the development of SSCs in a cohort of 1514 patients who underwent allo-HSCT for hematologic malignancies was further investigated. ME load at the HLA-DPB1 locus was measured using the HLAMatchmaker module incorporated in HLA Fusion software, and the PS for mismatched HLA-DPB1 was calculated using the HSCT module from the PIRCHE online matching service. ResultsIn multivariable analysis after adjusting for baseline risk factors, higher ME, PS-I, and PS-II in the GVH direction, but not in the HVG direction, were associated with an increased risk of SSCs (ME: subdistribution hazard ratio [SHR] 1.58, p = .01; PS-I: SHR 1.59, p = .009; PS-II: SHR 1.71, p = .003). In contrast, nonpermissive HLA-DPB1 mismatches defined by the conventional T-cell epitope algorithm were not predictive of the risk of SSCs. Moreover, posttransplant cyclophosphamide-based GVHD prophylaxis was associated with a reduced risk of SSC (SHR 0.34, p = .021). ConclusionsThese results indicate for the first time that increased GVH alloreactivity could contribute to the development of SSCs in allo-HSCT survivors.Keywords
This publication has 41 references indexed in Scilit:
- Delivering Care to Long-Term Adult Survivors of Hematopoietic Cell TransplantationJournal of Clinical Oncology, 2012
- Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reducedLeukemia, 2012
- Reduced Mortality after Allogeneic Hematopoietic-Cell TransplantationNew England Journal of Medicine, 2010
- Hematopoietic Stem Cell TransplantationA Global PerspectiveJAMA, 2010
- Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell TransplantationJournal of Clinical Oncology, 2010
- Alloreactive microenvironment after human hematopoietic cell transplantation induces genomic alterations in epithelium through an ROS-mediated mechanism: in vivo and in vitro study and implications to secondary neoplasiaLeukemia, 2010
- Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working PartyBlood, 2008
- Nonmelanoma Skin and Mucosal Cancers After Hematopoietic Cell TransplantationJournal of Clinical Oncology, 2006
- Host-reactive CD8+ memory stem cells in graft-versus-host diseaseNature Medicine, 2005
- The extent of HLA class II allele level disparity in unrelated bone marrow transplantation: analysis of 1259 National Marrow Donor Program donor–recipient pairsBone Marrow Transplantation, 2000